# Luminate Medical

**Source:** https://geo.sig.ai/brands/luminate-medical  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** luminate.ie  
**Last Updated:** 2026-04-14

## Summary

Dublin oncology device company developing at-home scalp cooling to prevent chemo hair loss; $22M YC and 8VC-backed with $15M Atlantic Bridge Series A pursuing FDA clearance for at-home oncology care model.

## Company Overview

Luminate Medical is a Dublin, Ireland-based healthcare technology company developing patient-centered oncology care devices — most notably a next-generation scalp cooling system that prevents or reduces chemotherapy-induced hair loss (alopecia), one of the most psychologically distressing side effects of cancer treatment. Backed by Y Combinator, 8VC, and Atlantic Bridge with $22 million raised total including a $15 million Series A led by Atlantic Bridge in 2024 and a €6.4 million Irish Government grant in 2025, Luminate is pursuing FDA clearance for US market entry with first commercial revenues expected in 2025.

Luminate's scalp cooling technology applies controlled cooling to the scalp during and after chemotherapy infusions — reducing blood flow to hair follicles and limiting chemotherapy drug uptake at the follicle level that causes hair loss. The innovation focuses on improving patient experience over existing clinical devices: making cooling sessions more comfortable during 2-4 hour infusions, enabling at-home use rather than clinic-only delivery, and building a connected device platform that enables remote monitoring of patient adherence and cooling efficacy. The at-home model addresses a significant access gap — most patients currently travel to clinical settings for each scalp cooling session.

In 2025, Luminate competes in the scalp cooling and oncology device market with Paxman (UK, dominant FDA-cleared provider), Dignicap (Swedish, FDA-cleared scalp cooling), and home oncology care startups for the scalp cooling device segment. Scalp cooling is covered by select US insurers (Cigna, Aetna, BCBS in some states) but reimbursement remains inconsistent — reimbursement pathway development is as strategically important as regulatory clearance for commercial success. The Irish Government grant reflects Ireland's health technology sector strategy and Luminate's IP development credentials. The 2025 strategy focuses on FDA clearance completion, launching the at-home scalp cooling system commercially, and building the connected device platform that links patients to their oncology care team through device adherence and efficacy data.

## Frequently Asked Questions

### What is Luminate Medical?
Luminate Medical is an Ireland-based medical device company founded in 2020 that develops innovative cancer care technology enabling treatment at home. The company is part of Y Combinator's S21 batch and specializes in patient-centered systems for at-home cancer therapy, including a revolutionary hair-saving chemo helmet.

### What products and services does Luminate Medical offer?
Luminate Medical offers a hair-saving chemo helmet (scalp cooling device), at-home cancer treatment systems, and smart patient-centered therapy platforms. Their solutions focus on chemotherapy side-effect mitigation and home-based oncology care through FDA-approved medical devices (pending approval).

### Who are Luminate Medical's target customers?
Luminate Medical serves cancer patients undergoing chemotherapy, oncology centers, and healthcare providers. Their solutions are designed for anyone requiring innovative at-home cancer care technologies globally.

### When was Luminate Medical founded?
Luminate Medical was founded in 2020. The company participated in Y Combinator's Summer 2021 (S21) batch.

### Where is Luminate Medical located?
Luminate Medical is based in Galway, Ireland.

### How much funding has Luminate Medical raised?
Luminate Medical has raised $22M in total funding, including a $15M Series A round in September 2024 led by Atlantic Bridge and $2.5M in additional funding in December 2024. The company also received a €6.4M grant from the Irish Government DTIF in April 2025 for at-home cancer treatment system development.

### Who are Luminate Medical's investors?
Luminate Medical's investors include Atlantic Bridge (Series A lead), Steve Pacelli, Finn Murphy, Faber, Elkstone, Y Combinator, Artis Ventures, Metaplanet, Lachy Groom, 8VC, SciFounders, Gaingels, Pareto, and Lynett Capital.

### When will Luminate Medical start generating revenue?
Luminate Medical expects to generate its first revenues in 2025. FDA approval is currently pending for their US market launch.

### What technology does Luminate Medical use for hair preservation during chemotherapy?
Luminate Medical uses scalp cooling technology in their hair-saving chemo helmet. This innovative device helps mitigate chemotherapy side effects, specifically hair loss, for cancer patients undergoing treatment.

### What are Luminate Medical's recent developments?
Recent developments include raising $22M in total funding (including $15M Series A in September 2024 and $2.5M in December 2024) and receiving a €6.4M Irish Government DTIF grant in April 2025. The company is awaiting FDA approval and expects first revenues in 2025.

## Tags

healthtech, saas, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*